Key highlights
- Confirmed objective response rate of 33% observed in efficacy-evaluable patients
- Preliminary median progression-free survival reached 7.4 months with a 6-month PFS rate of 62%
- Confirmed ORR increased to 44% specifically among patients with PIK3CA mutations
- Overall disease control rate stood at 83% across the evaluable patient population
- Low discontinuation rate of 5% due to treatment-related adverse events during the trial
Phase 2 Clinical Outcomes
The PIK-201 trial evaluated PIKTOR, an all-oral combination of serabelisib and sapanisertib, administered alongside paclitaxel for patients with advanced endometrioid endometrial cancer and PAM pathway mutations. As of October 30, 2026, confirmed objective responses were identified in 12 of 36 evaluable patients. The safety profile indicated that treatment-related hyperglycemia occurred in 12% of patients and stomatitis in 21%, with both side effects being predominantly low-grade. These results were achieved in a heavily pre-treated population where patients had a median of two prior lines of therapy, ranging from one to four lines.
Strategic Development Path
- Advancement of PIKTOR into a Phase 3 registrational trial pending regulatory alignment
- Targeting of the high-prevalence PI3K pathway alterations in endometrial cancer
- Utilization of multi-node inhibition to extend progression-free survival beyond standard chemotherapy
- Expansion of clinical evidence following the FDA Fast Track designation granted in August 2026
- Continuation of the Phase 1b/2 PIK-101 trial in advanced breast cancer with data expected in 2027
Management Perspective on Efficacy
“We believe these data support the multi-nodal PAM targeting hypothesis, whereby more complete inhibition of the pathway may drive durable responses and extend progression-free survival without the safety limitations of single-node inhibitors.”
Corporate and Financial Standing
Faeth Therapeutics maintains a robust liquidity position with $174.8 million in cash and marketable securities as reported in early November 2026. This capital is projected to support ongoing operations and clinical development for at least 12 months. The company, which rebranded to its current name and ticker symbol FTH in June 2026, currently reports no revenue or order backlog as it focuses on its clinical-stage pipeline. Market response to the Phase 2 data saw the share price increase by 10.69%, reflecting investor interest in the upcoming Phase 3 transition.
Down 57.9% since our story on 9 Nov: $22.05 when we broke it → $9.28 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $19.44 |
|---|---|
| 20 Oct | $20.79 |
| 21 Oct | $20.57 |
| 22 Oct | $20.10 |
| 23 Oct | $17.08 |
| 26 Oct | $16.83 |
| 27 Oct | $19.11 |
| 28 Oct | $19.20 |
| 29 Oct | $18.75 |
| 30 Oct | $18.69 |
| 2 Nov | $19.23 |
| 3 Nov | $19.65 |
| 4 Nov | $19.99 |
| 5 Nov | $19.92 |
| 6 Nov | $22.05 |
| 9 Nov | $12.68 |
| 10 Nov | $12.92 |
| 11 Nov | $13.35 |
| 12 Nov | $10.65 |
| 13 Nov | $10.03 |
| 16 Nov | $9.28 |
| Date | Announcement | Amount |
|---|---|---|
| 03 Nov 2026 | Third quarter 2026 financial results and operational updatesSource: morningstar.com | – |
| 17 Aug 2026 | FDA granted Fast Track designation to PIKTOR plus paclitaxel in biomarker-selected advanced endometrial cancerSource: businesswire.com | – |
| 04 Aug 2026 | Second quarter 2026 financial results and operational updatesSource: businesswire.com | – |
| 15 Jun 2026 | Corporate name changed to Faeth Therapeutics, Inc. and ticker symbol changed to FTHSource: investors.faeththerapeutics.com | – |
| 15 May 2026 | First quarter 2026 financial results and corporate updateSource: investors.faeththerapeutics.com | – |
| 18 Feb 2026 | Acquisition of Faeth Therapeutics and concurrent private placementSource: businesswire.com | $200.0 Million |
Management commentary
“In PIK-201, PIKTOR delivered a preliminary estimated median PFS of 7.4 months, which we believe compares favorably to the 3-4 months typical for salvage chemotherapy alone, or the 6-7 months observed with newer treatments including TOPO1-based ADCs.”
| Share price | $22.05 |
|---|---|
| Market cap | $570M |
| 1-month price change | -11.52% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Current report filing by Faeth Therapeutics announcing positive topline Phase 2 results for the PIK-201 trial.
Track Faeth Therapeutics, Inc. live
Get the next Faeth Therapeutics, Inc. SEC filing seconds after it lands.